Maze Therapeutics price to book ratio MAZE

Market value divided by the book value of the company's net assets, since 2025.

Today, Oct 23, 2026: 3.8×
Peer median: 5.6×

Maze Therapeutics' price to book ratio is 3.8× as of Oct 23, 2026.

The median for 10 biotech stocks of a similar size is 5.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.8×	2.8×	6.4×
2025	5.3×	1.4×	5.5×

Against its peers

Companies in Biotechnology nearest Maze Therapeutics' size, closest first, today.

Company	Price to book ratio
MAZEMaze Therapeutics	3.8×
VCELVericel	5.9×
ADMAAdma Biologics	5.9×
MGTXMeiraGTx	4.1×
KRYSKrystal Biotech	6.8×
RGENRepligen	4.7×
TECHBIO-TECHNE	5.4×
HALOHalozyme Therapeutics	99.3×
PLXProtalix BioTherapeutics	2.9×
NBIXNeurocrine Biosciences	3.9×
EXELExelixis	8.7×
Peer median	5.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Maze Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.